Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window.

Cancer Biol Med · 2025 · PMC11976706 · PMID 39927692

Europe PMC DOI

hedged sentence

0.1770

closest p · 3.5× alpha

0.1770

boldest claim

The sentences

did not reach statistical significanceP = 0.177not close (p > 0.1)

Specifically, patients achieving complete response/partial response (CR/PR) who received ≥ 18 months of ICI therapy had a trend toward longer median OS than those treated for 6 to 18 months, but the difference did not reach statistical significance ( P = 0.177).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.